Trillium Asset Management LLC lowered its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 30.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,479 shares of the company’s stock after selling 5,459 shares during the quarter. Trillium Asset Management LLC’s holdings in Alkermes were worth $723,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in ALKS. Dimensional Fund Advisors LP boosted its position in Alkermes by 1.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 198,135 shares of the company’s stock worth $10,076,000 after acquiring an additional 2,027 shares during the period. Bank of Montreal Can lifted its holdings in shares of Alkermes by 92.5% in the fourth quarter. Bank of Montreal Can now owns 13,194 shares of the company’s stock valued at $723,000 after buying an additional 6,341 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Alkermes by 5.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 493,515 shares of the company’s stock valued at $27,011,000 after buying an additional 23,712 shares during the period. State of Alaska Department of Revenue acquired a new stake in shares of Alkermes in the fourth quarter valued at $612,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Alkermes in the fourth quarter valued at $114,000.
In other Alkermes news, Director Richard F. Pops sold 50,000 shares of the stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $44.02, for a total value of $2,201,000.00. Following the transaction, the director now directly owns 716,352 shares in the company, valued at approximately $31,533,815.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael J. Landine sold 20,000 shares of the stock in a transaction on Thursday, May 17th. The shares were sold at an average price of $46.14, for a total value of $922,800.00. Following the completion of the transaction, the senior vice president now owns 192,644 shares in the company, valued at $8,888,594.16. The disclosure for this sale can be found here. Insiders have sold a total of 228,842 shares of company stock valued at $10,408,590 over the last ninety days. Insiders own 5.51% of the company’s stock.
Alkermes stock traded up $1.15 during trading hours on Thursday, hitting $50.14. The stock had a trading volume of 1,085,335 shares, compared to its average volume of 1,069,057. The company has a quick ratio of 2.52, a current ratio of 2.83 and a debt-to-equity ratio of 0.24. The stock has a market cap of $7.60 billion, a price-to-earnings ratio of -135.51 and a beta of 1.82. Alkermes Plc has a fifty-two week low of $41.15 and a fifty-two week high of $71.22.
Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, April 26th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). Alkermes had a negative return on equity of 3.13% and a negative net margin of 16.18%. The company had revenue of $225.20 million during the quarter, compared to analyst estimates of $219.51 million. During the same period in the previous year, the company posted ($0.18) earnings per share. The company’s quarterly revenue was up 17.4% on a year-over-year basis. analysts expect that Alkermes Plc will post -0.66 earnings per share for the current fiscal year.
A number of equities research analysts have recently issued reports on the company. Morgan Stanley reaffirmed an “equal weight” rating and set a $67.00 target price (up from $60.00) on shares of Alkermes in a research report on Friday, February 23rd. Zacks Investment Research lowered Alkermes from a “buy” rating to a “hold” rating in a research report on Monday, May 28th. ValuEngine raised Alkermes from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 31st. Credit Suisse Group upped their price target on Alkermes from $66.00 to $70.00 and gave the company an “outperform” rating in a research report on Friday, February 16th. Finally, Citigroup raised Alkermes from a “neutral” rating to a “buy” rating and set a $62.00 price target on the stock in a research report on Wednesday, May 16th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. Alkermes presently has a consensus rating of “Hold” and an average price target of $59.08.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.